DSIP 10mg

Research Overview

DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) was first isolated in 1974 by the Schoenenberger-Monnier group at the University of Basel, Switzerland, from the cerebral venous blood of rabbits in electrically induced slow-wave sleep. DSIP-like immunoreactivity has since been detected in the hypothalamus, limbic system, pituitary gland, and human breast milk.[1][17]

DSIP remains neuroscience's "unresolved riddle": despite 50+ years of study, no specific gene coding for a DSIP precursor has been identified, and no dedicated receptor has been cloned. Sequence analysis suggests homology with the 324–332 fragment of human lysine-specific histone demethylase 3B (KND peptide, JMJD1B gene).[1]

Originally pursued as a "somnogenic molecule" to cure insomnia, the therapeutic rationale shifted to that of a "programming modulator" or adaptogen — stabilizing neuronal activity and restoring homeostasis under stress or disrupted circadian rhythms. Research spans 8+ indication categories across neurology, addiction medicine, oncology, cardiology, and gerontology.[9]

Discovery and historical context: The Schoenenberger-Monnier program at Basel pursued the "humoral hypothesis of sleep" — that a circulating factor accumulating during wakefulness drives the transition into slow-wave sleep. Cerebral venous blood from rabbits in electrically-induced thalamic-stimulated sleep was dialyzed and infused into recipient rabbits, reproducing the delta-EEG signature. The active fraction was isolated, sequenced as a linear nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, MW 848.81 Da), and synthesized — the synthetic preparation reproduced the EEG-modifying activity of the natural extract.[1][17]

Research framework: DSIP exhibits an unusual pharmacological profile that distinguishes it from receptor-targeted neuropeptides — bell-shaped dose-response, partial blood-brain-barrier penetration, ~15-min plasma half-life with rapid N-terminal tryptophan cleavage by aminopeptidases, and no cloned receptor. The aminopeptidase-resistant analog [D-Ala²]DSIP and the more-potent KND peptide (WKGGNASGE, single Asp→Asn substitution at position 5) are the standard structural tools used in modern preclinical studies to dissect the underlying signaling. Investigators studying related stress-modulating and neuroprotective peptides commonly cross-reference our Selank, Semax, and Epithalon pages for parallel adaptogen pharmacology and circadian-rhythm modulation in rodent models.[9]

Mechanism of Action

DSIP's exact mechanism remains partially obscure — the "unresolved riddle" stems from the absence of a cloned receptor or identified gene. However, extensive research characterizes its interactions across multiple receptor systems and signaling cascades.[1]

Receptor Targets

Downstream Signaling

Dose-Response: Bell-Shaped Curve

Key analog: KND peptide (WKGGNASGE) — differs by single amino acid (Asn vs Asp at position 5); more potent antioxidant; greater reduction in myocardial infarction (19.1% vs 28.7%).[8]

Integrative Model: "Programming Modulator"

The absence of a single high-affinity receptor — combined with documented modulatory activity at NMDA, opioid, α₁-adrenergic, MAPK, MAO-A, antioxidant-enzyme, c-Fos, and mitochondrial respiration endpoints — supports the Schoenenberger framework that DSIP acts as a state-dependent neuronal-tone stabilizer rather than a classical agonist or antagonist. Computational analyses propose homology with the 324-332 fragment of human lysine-specific histone demethylase 3B (JMJD1B), suggesting endogenous DSIP-like activity may arise from proteolytic cleavage of a larger precursor rather than from a dedicated DSIP gene.[1][9]

Pharmacokinetic Constraints

The ~15-min plasma half-life — driven by N-terminal Trp cleavage by aminopeptidases — has shaped the design of the modern DSIP literature. This rapid peripheral degradation explains the wide spread in published active amounts across animal studies (sub-µg ranges with direct CNS exposure versus mg-range systemic designs). The aminopeptidase-resistant analog [D-Ala²]DSIP and the KND analog were developed to address this constraint.[7][8]

Stress-Axis & HPA Modulation

In stress paradigms, DSIP prevents c-Fos induction in the paraventricular nucleus, lowers basal corticotropin output, and blocks cortisol release — effects that are reversible by NMDA-receptor agonists and by naloxone, implicating combined NMDA-modulation and opioid-receptor pathway as the mechanistic substrate. Sudakov 1983 and Salieva 1989 showed that systemic DSIP increased animal resistance to acute emotional stress, paralleling the antidepressant-like reduction in pain-and-depression scores observed in the Larbig 1984 chronic-pain pilot.[18][21]

Research Applications

DSIP research spans 8+ indication categories across neurology, addiction, oncology, and gerontology:

1. Sleep Regulation & Insomnia — Increases delta (slow-wave) sleep 39–54% in rabbits; 59% median increase in total sleep time in a small human study; a 7-night study in chronic insomnia reported normalized sleep efficiency.[3][4]
2. Withdrawal Syndrome Studies — Opiate (n=60) and alcohol (n=47) withdrawal-symptom endpoints were reported in early clinical studies.[2]
3. Stress Adaptation & HPA Modulation — Reduces stress-induced metabolic disorders; lowers basal corticotropin; blocks cortisol release; prevents c-fos expression during emotional stress.[18]
4. Nociception — Dose-dependent antinociceptive effect (blocked by naloxone); reduced pain in 6/7 chronic pain subjects.[11][5]
5. Neuroprotection & Stroke Models — DSIP/KND reduced brain infarction volume during reperfusion; accelerated motor function recovery in focal stroke.[8][7]
6. Cardioprotection — Reduces myocardial infarction size (IA/AAR 28.7% vs 42.1% control); stabilizes mitochondrial respiration. ⚠️ 100% mortality if given during occlusion phase.[8]
7. Epilepsy & Anticonvulsant — In the metaphit audiogenic seizure model, DSIP alone did not significantly alter seizure latency, but potentiated the anticonvulsive activity of an otherwise non-protective valproate dose; intranigral DSIP and its analogs have also been studied for effects on movement and convulsive activity.[16][20]
8. Geroprotection & Oncology — Maximum lifespan +24.1% in SHR mice; total tumors ↓2.6-fold; mammary carcinoma ↓5-fold; chromosomal aberrations ↓22.6%.[10]
9. Mitochondrial & Antioxidant Research — Stabilizes NADH-dehydrogenase, enhances oxidative phosphorylation, stimulates SOD/catalase/glutathione peroxidase — used as a tool peptide for studying mitochondrial cytoprotection under hypoxic/ischemic stress.[9]
10. HPA Axis Stress Resistance — Prevents c-Fos induction in paraventricular nucleus, lowers basal corticotropin, increases resistance to acute emotional stress in rodent models (Sudakov 1983, Salieva 1989).[18][21]

Comparative Research Context

DSIP occupies a unique position in the adaptogen / programming-modulator literature alongside other stress-and-circadian-rhythm peptides such as Selank, Semax, Epithalon, and Pinealon. Where Selank acts via tuftsin-related immunomodulatory and anxiolytic pathways and Semax activates BDNF expression in the hippocampus, DSIP appears to operate through state-dependent stabilization of multiple receptor systems without a dedicated high-affinity target. Researchers comparing DSIP with related adaptogen peptides commonly cross-reference our Selank, Semax, and Epithalon pages for parallel preclinical pharmacology — particularly for studies addressing slow-wave sleep, oxidative stress resistance, and HPA-axis modulation in rodent models. The KND peptide and [D-Ala²]DSIP analogs remain the standard tools for distinguishing DSIP-specific effects from generic peptide vehicle effects in mechanism-of-action studies.

Preclinical Research Summary

Key Preclinical Studies

Clinical / Human Studies

Safety Summary